Company profile: Xoft
1.1 - Company Overview
Company description
- Provider of electronic brachytherapy (eBx) systems for radiation oncology, including the Elekta Xoft Axxent system with miniaturized X-ray source, Axxent Controller, SPX Controller for surface treatments, Axxent X-ray Source, balloon and extended balloon applicators for intracavitary and intraoperative therapy, and Radion Hub Peer Review cloud software for network-wide peer review to improve patient safety and quality care.
Products and services
- Axxent X-ray Source: A miniaturized HDR-enabled X-ray emitter delivering a precise radiation dose directly to the cancerous site, sparing surrounding healthy tissue in electronic brachytherapy applications
- Balloon Applicators: Intracavitary-use devices that enable targeted delivery of intraoperative radiation therapy, supporting accelerated partial breast treatments by accurately positioning the Axxent source within the surgical cavity
- Elekta Xoft Axxent Electronic Brachytherapy (eBx) System: A clinical-grade platform using a miniaturized X-ray source to deliver targeted radiation to the tumor bed, minimizing exposure to adjacent healthy tissue in radiation oncology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Xoft
Predilife
HQ: France
Website
- Description: Provider of predictive medicine solutions that combine proven medical techniques (genetic testing, medical imaging) with mathematical models and extensive statistical data to assess individual risk profiles for serious diseases. Offers a breast cancer five-year risk assessment with personalized follow-up and recommendations, and multi-pathology assessments for major cancers and cardiovascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Predilife company profile →
Janux Therapeutics
HQ: United States
Website
- Description: Provider of immunotherapies that activate T cells in the tumor microenvironment while sparing healthy tissue, including PSMA-TRACTr (JANX007) for metastatic castration-resistant prostate cancer and EGFR-TRACTr (JANX008) in Phase 1 for carcinomas, built on proprietary TRACTr and TRACIr bispecific platforms; partnered with Merck to develop next-generation T cell engager immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Janux Therapeutics company profile →
Lindis Blood Care
HQ: Germany
Website
- Description: Provider of a medical device for removing cancer cells from intraoperative blood during cancer surgeries to enable autologous blood transfusion (CATUVAB), and a multicenter clinical certification study (REMOVE) assessing the device’s efficacy and safety in tumor cell removal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lindis Blood Care company profile →
Lengo Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical solutions focused on discovering and developing cancer treatments, including AYVAKIT/AYVAKYT (avapritinib) for systemic mastocytosis and gastrointestinal stromal tumors with PDGFRA exon 18 mutations. Offers clinical trials, a U.S. patient support program for access and affordability, and a scientific platform to develop highly selective medicines for mast cell disorders and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lengo Therapeutics company profile →
Iambic Therapeutics
HQ: United States
Website
- Description: Provider of an AI-driven drug-discovery platform to optimize drug profiles and identify novel mechanisms of action, featuring NeuralPlexer (3D physics-based generative diffusion for protein-ligand structures), OrbNet (protein-ligand binding energetics), PropANE (multi-parameter lead selection), and Magnet (generative molecular design), plus a first-in-class CDK2/4 candidate for cyclin D- and E-driven cancers with reduced off-target toxicities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iambic Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Xoft
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Xoft
2.2 - Growth funds investing in similar companies to Xoft
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Xoft
4.2 - Public trading comparable groups for Xoft
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →